SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer

Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhodapkar, Kavita M, Gettinger, Scott N, Das, Rituparna, Zebroski, Henry, Dhodapkar, Madhav V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782159/
https://www.ncbi.nlm.nih.gov/pubmed/24073380
http://dx.doi.org/10.4161/onci.25205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782159/
https://www.ncbi.nlm.nih.gov/pubmed/24073380
http://dx.doi.org/10.4161/onci.25205

Ejemplares similares